An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Last updated on April 2022Recruitment
- Recruitment Status
- Approved for marketing
Summary
- Type
- Expanded Access
Tracking Information
- NCT #
- NCT01995734
- Collaborators
- Not Provided
- Investigators
- Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals